HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV
Top Cited Papers
Open Access
- 24 February 2014
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 60 (1), 98-105
- https://doi.org/10.1002/hep.27095
Abstract
Data show that viral genotype 1 may increase the risk of cirrhosis and hepatocellular carcinoma (HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection. However, the effect of HCV genotype 3 on cirrhosis and HCC risk is uncertain. We identified patients with active HCV infection, confirmed by positive polymerase chain reaction (PCR) and a known HCV genotype, from the VA HCV Clinical Case Registry between 2000 and 2009. We examined the effect of HCV genotype on the risk of cirrhosis and HCC in a Cox proportional hazards model adjusting for patients' age, period of service (World War I/II, Vietnam era, post‐Vietnam era), race, gender, human immunodeficiency virus (HIV) infection, alcohol use, diabetes, body mass index, and antiviral treatment receipt. Of the 110,484 patients with active HCV viremia, 88,348 (79.9%) had genotype 1, 13,077 (11.8%) genotype 2, 8,337 (7.5%) genotype 3, and 1,082 (0.9%) patients had genotype 4 infection. Despite being younger, patients with genotype 3 had a higher risk of developing cirrhosis (unadjusted hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.32‐1.50) and HCC (unadjusted HR = 1.66, 95% CI = 1.48‐1.85) than HCV genotype 1 patients. After adjustment for prespecified demographic, clinical, and antiviral treatment factors, the risk of cirrhosis and HCC was 31% (adjusted HR = 1.31, 95% CI = 1.22‐1.39) and 80% (adjusted HR = 1.80, 95% CI = 1.61‐2.03) higher in patients with genotype 3 compared to genotype 1 infected patients. Conclusion: HCV genotype 3 is associated with a significantly increased risk of developing cirrhosis and HCC compared to HCV genotype 1. This association is independent of patients' age, diabetes, body mass index, or antiviral treatment. (Hepatology 2014;60:98–105)Keywords
This publication has 23 references indexed in Scilit:
- Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C InfectionPLOS ONE, 2013
- Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide PolymorphismsPLOS ONE, 2011
- Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C InfectionGastroenterology, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Clinical Case Registries: Simultaneous Local and National Disease Registries for Population Quality ManagementJournal of the American Medical Informatics Association, 2009
- Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysisJournal of Hepatology, 2009
- Predictors of response of U.S. veterans to treatment for the hepatitis C virusJournal of Hepatology, 2007
- Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosisGut, 2004
- Natural history of chronic hepatitis CJournal of Hepatology, 2002
- Natural history of chronic hepatitis CJournal of Hepatology, 2002